NCT00862225已完成2 期
Randomized, Double-blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are Sensitized to Grasses
Max Zeller Soehne AG1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
研究概览
简要总结
Randomised, double-blind and prospective clinical study to examine the mechanism of action of the Petasites hybridus leaf extract IG-RD-001 (Ze-339, petasol butenoate complex) compared to desloratadine and placebo in patients with seasonal allergic rhinitis of all degrees of severity (provoked by grasses). The treatment arm with desloratadine is an established standard treatment and is intended to ensure the comparative methodology of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Allergic rhinitis since at least 2 years
- •Age: = > 18 years
- •Consent in accordance with the AMG (=German Drug Law)
- •Positive skin test, skin prick test or positive RAST for grasses The skin prick test is positive if the wheal is >= 3 mm greater than control; a skin test is positive if the wheal is >= 7 mm greater than control
- •Women of childbearing potential have to use a highly effective method of birth control (according CPMP/ICH/286/95 Note 3) during the duration of the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.
排除标准
- •Past or current psychological disease or disorder which can impair the study participant's ability to understand the study requirements, t take part in the study or give consent after briefing
- •Past or current alcohol or medication dependency or abuse
- •Bronchial asthma (FEV < 80 %)
- •Glaucoma, cataract or ocular herpes simplex
- •Clinically relevant deviations from normal laboratory parameters (if known)
- •Antihistamines with a long-term effect
- •Malignant diseases, including in the patient's case history
- •Parasites
- •Study participants who are taking part in another study or took an investigational product during the last 4 weeks before the start of treatment
- •Progressive systemic diseases such as tuberculosis, leukoses, collagenoses, multiple sclerosis, Aids, HIV infection and other autoimmune diseases
- •Other types of rhinitis with different causes, acute or chronic sinusitis
- •Pregnancy or lactation
- •Serious internal diseases, e.g. serious decompensated diseases of the heart, liver, kidneys or diabetes mellitus
- •Patients with rarely occurring hereditary problems galactose-intolerance, Lapp-lactase-deficiency or glucose-galactose-malabsorption
- •Pre-existing liver damage
- •The use of non-steroidal antirheumatic agents (NSAR)
- •Hypersensitivity towards one of the ingredients in the investigational product
- •Not adhering to the following periods of abstention before the nasal provocation test: 3 days for DNCG, nedocromil, nasal and oral antihistamines, and tricyclic psychotropic drugs, 1 months systemic treatment with glucocorticoids, 14 days for nasal and topical corticosteroids, 1 week for antihistamines, and 1 day for α-adrenergic drugs. The use of ACE inhibitors or ß-blockers
- •Previous organ transplants
研究组 & 干预措施
1
Placebo Comparator
干预措施: Placebo (Drug)
2
Active Comparator
干预措施: Desloratadin (Drug)
3
Experimental
干预措施: IG-RD-001 / Ze 339 (Drug)
结局指标
主要结局
The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
时间窗: 0-24 hours post nasal provocation test
次要结局
- Clinical symptom score (rhinorrhoea, nasal congestion, nasal itching and sneezing), assessment by the investigator (nasal secretion, irritation, occurrence of systemic symptoms), mediators in the serum, nasal secretion, nasal curettage and biopsy(0-24h post nasal provocation test)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)Rhinitis, Allergic, PerennialNCT00092118Organon and Co1,992
已完成
1 期
A Study of CDX-0159 in Patients With Prurigo NodularisPrurigo NodularisNCT04944862Celldex Therapeutics24
Unknown
2 期
Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial VaginosisHUDC_VTHaudongchunBacterial VaginosisNCT03357666Haudongchun Co., Ltd.150
已完成
不适用
Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD PatientsNon Alcoholic Fatty LiverNCT02923804Pronova BioPharma172
招募中
不适用
Nafamostat Efficacy in Phase 3 Registrational CRRT StudyAcute Kidney InjuryNCT06150742Talphera, Inc70